Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Applied DNA Customer ÚHKT Initiates Phase I CAR T-Cell Therapy Trial with Linea DNA
Details : CAR123 an investigational CD123-specific autologous CAR T-cell therapy by the ÚHKT for the treatment of relapsed and/or refractory acute myeloid leukemia (AML).
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 18, 2024
Lead Product(s) : DNA-based Covid-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study demonstrated safety and immunogenicity of a linear DNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines. Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : DNA-based Covid-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LinearDNA COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : EvviVax
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : On the assumption that both trials’ primary endpoints are met, the Company and EvviVax expect to apply for a USDA APHIS conditional license (9 CFR 102.6) for a LinearDNA COVID-19 vaccine candidate for domestic felines.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
November 30, 2020
Lead Product(s) : LinearDNA COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : EvviVax
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LineaDNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BALB/c mice received linear DNA at day 1 and a booster vaccination on day 21. All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
July 17, 2020
Lead Product(s) : LineaDNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LineaDNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Takis Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
July 17, 2020
Lead Product(s) : LineaDNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Takis Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : First injections of the DNA vaccine candidates against the Spike protein of the SARS-CoV-2 virus have produced neutralizing antibodies that block the infection of cultured human cells by SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
May 04, 2020
Lead Product(s) : DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Linear DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary testing of plasmid-based vaccine templates shows strong immune responses, catalyzes testing of linear dna-based constructs set to begin immediately.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
April 15, 2020
Lead Product(s) : Linear DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate
Details : The newly added 5th linear DNA vaccine candidate encodes an engineered fusion protein of a COVID-19 Spike domain with an immunomodulator moiety.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Not Applicable
April 02, 2020
Lead Product(s) : DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Linear DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Takis Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Applied DNA is expected to enter large-scale production of candidates in march; preclinical testing in animals by takis biotech anticipated to begin in calendar Q2 2020.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Linear DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Takis Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Linear DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Takis Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Applied DNA and Takis Biotech partner on coronavirus vaccine
Details : LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 10, 2020
Lead Product(s) : Linear DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Takis Biotech
Deal Size : Undisclosed
Deal Type : Collaboration